Prodrome Sciences Inc.

Team

Dr. Dayan Goodenowe

Founder

Dr. Dayan Goodenowe

Dr. Goodenowe has an undergraduate degree in Chemistry from the University of Saskatchewan and a Ph.D. in Medicine from the University of Alberta. His principal research interest is to understand the biochemical basis of health and disease. In 1999, Dr. Goodenowe invented and patented an advanced mass spectrometry technology called Non-Targeted Complex Sample Analysis, which enabled researchers, for the first time, to comprehensively measure and monitor the biochemistry of complex biological systems such as human health and disease.

In 2000, Dr. Goodenowe founded Phenomenome Discoveries Inc. to apply his advanced mass spectrometry technology to the discovery of novel biochemical disease mechanisms which could be used for diagnosis and therapeutic targeting of human disease. Dr. Goodenowe’s technology was successfully used by Phenomenome Discoveries to discover diagnostic biomarkers of colon cancer, pancreatic cancer, ovarian cancer, Alzheimer’s disease, autism, and multiple sclerosis. In addition, Dr. Goodenowe’s technology identified putative disease modifying therapeutic targets for these diseases.

In 2016, Dr. Goodenowe founded Prodrome Sciences Inc. to move beyond the initial diagnostic prototypes and concepts being developed at Phenomenome Discoveries. Dr. Goodenowe has since designed a new generation of diagnostics technology which is amenable to a robust, FDA-compliant, human health diagnostic system that can be installed in laboratories and hospitals around the world. Similarly, Dr. Goodenowe’s vision of Prodrome Sciences’ Therapeutics division is to implement robust clinical validation and implementation protocols for the commercialization of natural biochemical-based preventative therapeutics. Dr. Goodenowe is the inventor of numerous patents related to the diagnosis and treatment of cancer and neurodegenerative diseases.

Founding Team

Dr. Dayan Goodenowe

Dr. Dayan Goodenowe

President and Chief Executive Officer

Dr. Goodenowe is responsible for designing, implementing, and managing the scientific and business strategies of Prodrome Sciences. He has over 20 years of advanced laboratory, biochemistry, and mass spectrometry discovery and development experience. With an undergraduate degree in Chemistry, a Ph.D. in Medicine, and 16 patents covering analytical technology, bioinformatics, disease biomarkers and targets, and novel therapeutic drug compositions, he brings a breadth of knowledge across all areas related to the biochemical understanding of disease and the practical implementation of diagnostic and therapeutic solutions to disease management. Dr. Goodenowe has built from scratch and subsequently managed an ISO certified, FDA-compliant manufacturing facility and a CAP/CLIA certified laboratory facility.

Monte Gorchinski

Monte Gorchinski

Chief Financial Officer

Monte is responsible for Prodrome Sciences' financial and risk management operations and strategy. He brings over 25 years of strategic financial business experience working with Boards of Directors and senior management to Prodrome Sciences. Monte’s expertise includes financial analysis, procedures, business risks, taxation, compliance reporting, and management accountability. He was a public practice partner at PricewaterhouseCoopers LLP from 1988-2012 and has been a private business advisor since 2012.

Erika Shklanka

Erika Shklanka

Vice President, Operations

Erika is responsible for applying Prodrome Sciences' strategic vision to all areas of operations and to act as an intermediary between executive management and divisions to ensure that the company’s subsidiaries and divisions operate in a cohesive manner. Erika worked at Phenomenome Discoveries Inc. from 2012 to 2016, most recently as the Research Coordinator, where she gained both administrative and laboratory experience as well as gained a comprehensive operational understanding of Dr. Goodenowe’s technology from sample procurement to reporting results in publications and to patients. She now applies this operational experience to Prodrome Sciences’ facilities and projects. Erika completed her Bachelor of Science Honours in Microbiology and Immunology at the University of Saskatchewan.

Vijitha Senanayake

Dr. Vijitha Senanayake

Vice President, Clinical Research and Development

Dr. Senanayake applies his scientific expertise and management experience to Prodrome Sciences where he oversees clinical research from concept to product launch. He was employed at Phenomenome Discoveries Inc. from 2012 until 2016 as the senior clinical research scientist where he managed over 15 large preclinical and clinical projects related to plasmalogen restoration therapeutics and neurosciences. He was responsible for designing experimental studies, sample management and analysis, data analysis, manuscript writing, grant application writing, clinical protocol drafting, and liaising with various academic entities. Dr. Senanayake has a degree in Veterinary Medicine and a Ph.D. in nutritional biochemistry. Dr. Senanayake has managed a large clinical nutrition trial testing lipid modulating activities of various oils.

Yanqiu Jiang

Yanqiu Jiang

Vice President, Software Development and Design

Yanqiu applies her expertise to align the strategic vision of Prodrome Sciences with all areas of software development including programming to regulatory compliance. She worked at Phenomenome Discoveries Inc. from 2002 until 2016. Her role as Software Manager was to design, develop, and manage project-based programming infrastructure to be compliant with quality management systems and regulatory bodies. Yanqiu completed her Bachelor of Science in Computer Science at the University of Saskatchewan in Canada and also has BSc degrees in both physics and biology from the Normal Northeast University in China.

Audrey Trice

Audrey Trice

Office Manager

Audrey is responsible for developing, implementing, and overseeing Prodrome Sciences' administrative systems. She worked for Phenomenome Discoveries Inc. from 2008 to 2016, most recently as the Office Administrator, where she gained experience in managing administrative operations. Audrey has a Business Applications Specialist and Medical Office Assistant diploma from CDI College.

Ellen Liang

Ellen Liang

Interlaboratory Manager

Ellen coordinates laboratory operations between all of Prodrome Sciences' locations to implement and maintain uniform standard operating procedures and quality assurance systems. She worked at Phenomenome Discoveries Inc. from 2014 to 2016 as a Medical Laboratory Technician where she gained a thorough understanding of Dr. Goodenowe’s sample processing technology from extraction to results reporting. Ellen completed her Bachelor of Science in Chemistry from the University of Saskatchewan.

Ian Wright

Ian Wright

Board Member and Advisor

Ian Wright is the owner and founder of Strategic Innovations LLC. His role is to make connections between Scientists, Clinicians, and Industry and to develop strategies that will bring innovation and products to market as quickly, safely, and profitably as possible. Previously Mr. Wright led the Global Assay Development group for Siemens Healthcare Diagnostics. He also founded and led the Strategic Innovations Group for Siemens Healthcare, scouting for, and investing in, new technologies. He is currently Chief Business Advisor for the Applied Clinical Biosystems Research Institute at Cedars-Sinai, Los Angeles and Chief Strategic Advisor for the Precision Health Initiative at Cedars Sinai. He currently sits on the board of or acts as an advisor to a number of early stage IVDD and large bioscience companies. He is also a limited partner and advisor to Leading Edge Ventures, a Delaware based VC company. Mr. Wright sits on the program committee of BIO International and is a board member of the Delaware Biotechnology Association. He has been an advisor to the State of Delaware. He is a GlobalScot since 2010 (Global Ambassador for Bioscience for Scotland) and is a board member and Advocacy Chair for the Friends of the Bohemia River Association.

John Ryan

Dr. John Ryan

Board Member and Advisor

John L. Ryan, Ph.D., M.D., is Executive Vice President and Chief Medical Officer at Kadmon Corporation LLC. Dr. Ryan brings over 20 years of experience in drug discovery and development, including expertise in translational medicine and cancer biology. Prior to joining Kadmon, Dr. Ryan was CMO of Cerulean from July 2009 to March 2010 and before that Dr. Ryan was CMO at AVEO Pharmaceuticals from April 2006. Dr. Ryan spent 11 years at Wyeth where he last held the position of Senior Vice President of Translational Research and Head of the Department of Experimental Medicine. Prior to Wyeth, Dr. Ryan held positions in Clinical Research and Development at Genetics Institute and Merck Research Laboratories. Dr. Ryan received his B.Sc., M.Sc. and Ph.D. degrees from Yale University and his M.D. from the University of California, San Diego. He was a member of the Department of Internal Medicine at Yale, prior to joining Merck. Dr. Ryan was a board member, along with Dr. Goodenowe, at Phenomenome Discoveries Inc.

About Prodrome Sciences Inc.

Prodrome Sciences researches prodromes of diseases – how to detect them, what causes them, and how to return high-risk prodrome states back to a healthy state before the disease develops. We use our advanced diagnostic technology for blood tests to detect disease prodromes and in our natural therapeutic programs to restore an unhealthy, high-risk prodrome state to a healthy, low-risk state. Our goal is to reduce the number of people that develop and die from disease and to promote optimal health.

Keep in touch

©2018 Prodrome Sciences Inc.

Search